Mitoxantrone is a widely used anticancer agent. 1 and 2 The most distinctive disadvantage of this intercalating drug molecule is cardiotoxicity. 3 It seems that a solution of this problem has been found by the development of BBR2778 (Pixantrone) which is currently in phase III clinical trials in patients with Non-Hodgkin's Lymphoma. 4 This compound exhibits less cardiotoxicity 5 and it is evident that this advantage is based on the substitution of the 5,8-dihydroxy ...